MedBioSphere
Articles Videos The Web  
    

Spectrum Pharmaceuticals Launches

Selected Abstract

Spectrum Pharmaceuticals Launches Multi-Center, Phase 2 Clinical Trial of SPI-153 in Benign Prostatic Hypertrophy; * This Trial is in Addition to Launch of Phase 2 Clinical Trial of SPI-153 for Prostate Cancer Recently Announced.
IRVINE, Calif., April 13 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. today announced the launch of a multi-center phase 2 clinical trial to evaluate the safety and efficacy of SPI-153 as a treatment for patients with benign prostatic hypertrophy (BPH). The multi-center clinical trial ...
April 13, 2005; PR Newswire

Read the full article with a free-trial membership at HighBeam Research



Related Articles

1. Spectrum Pharmaceuticals Launches, Phase 2 Multicenter, Clinical Trial of SPI-153 in Hormone-Dependent Prostate Cancer; - Spectrum Now Has Three Anticancer Drugs in Phase 2 and One Drug in Phase 3 Clinical Trials.
2. Spectrum Pharmaceuticals Launches FUSILEV(TM).
3. Spectrum Pharmaceuticals Launches Multi-Center, Phase 2 Clinical Trial of SPI-153 in Benign Prostatic Hypertrophy; * This Trial is in Addition to Launch of Phase 2 Clinical Trial of SPI-153 for Prostate Cancer Recently Announced.
4. Spectrum Pharmaceuticals Launches Phase 2 Trial of Elsamitrucin in Refractory Non-Hodgkin's Lymphoma (NHL); The Expanded Phase 2 Trial Is Designed to Better Define the Appropriate Patient Population and NHL Subtypes That Are Responsive to Elsamitrucin.
5. Repeat: Spectrum Pharmaceuticals Launches Phase 2 Study of EOquin(TM) in Bladder Cancer; Study to Be Conducted at Up to 10 European Hospitals in Patients With Superficial Bladder Cancer.